Title
Avelumab Plus Methotrexate in Low-Risk Gestational Trophoblastic Tumors: What the TROPHAMET Trial Adds to First-Line Care
Highlights
In a multicenter phase 1/2 nonrandomized trial, adding the PD-L1 inhibitor avelumab to methotrexate produced a 96.2% human chorionic gonadotropin (hCG) normalization rate in low-risk gestational trophoblastic tumors (GTT).
The regimen was generally well tolerated, with one dose-limiting toxicity and no grade 4 or higher treatment-related adverse events.
After a median follow-up of 41 months, no relapses were observed, and fertility outcomes were favorable among patients wishing to conceive.
The findings suggest a potential path toward improving first-line outcomes in patients at higher risk of methotrexate resistance, but confirmatory comparative trials are still needed.
Study Background
Gestational trophoblastic tumors, often grouped under gestational trophoblastic neoplasia, are uncommon but highly treatable malignancies arising from pregnancy-related placental tissue. In patients with low-risk disease, defined in this study by a FIGO score of 6 or less, single-agent chemotherapy is usually effective and is associated with cure rates of about 70% in routine practice. Methotrexate remains one of the standard first-line agents, but a clinically important minority of patients require additional therapy because of incomplete response or chemoresistance.
At the same time, immunotherapy has changed the treatment landscape for several solid tumors. Avelumab is a monoclonal antibody targeting programmed cell death ligand 1 (PD-L1). Prior evidence of activity in chemotherapy-resistant gestational trophoblastic tumors created a rationale to test whether immune checkpoint blockade could improve outcomes earlier in the disease course, when tumor burden is lower and chemotherapy sensitivity may be greater.
The TROPHAMET study was designed to answer a practical clinical question: can avelumab safely intensify first-line methotrexate-based therapy without compromising the excellent fertility-preserving potential of treatment?
Study Design
TROPHAMET (Avelumab and Methotrexate in Low-Risk Gestational Trophoblastic Neoplasias as First-Line Treatment) was a multicenter, phase 1/2 nonrandomized clinical trial conducted at academic referral centers. Patients were treated between April 14, 2020, and December 5, 2023, and followed for a median of 41 months. Data analysis occurred from December 20, 2024, to July 3, 2025.
Eligible participants were female patients with low-risk GTT, defined by a FIGO score of 6 or less. The treatment strategy combined avelumab, 800 mg intravenously on day 1, with methotrexate, 1 mg/kg intramuscularly on days 1, 3, 5, and 7, alternating with oral folinic acid in 2-week cycles. Treatment continued until serum hCG normalized, followed by 3 consolidation cycles.
The phase 1 primary end point was dose-limiting toxicity (DLT), while the phase 2 primary end point was the rate of hCG normalization sufficient to permit treatment discontinuation. Key secondary considerations included safety, durability of response, relapse, and fertility outcomes.
Key Findings
Patient characteristics
Twenty-seven female patients received treatment, and 26 were assessable for efficacy. The median age was 35 years, with a range from 20 to 50 years. Disease risk was distributed across the low-risk spectrum: 8 patients (31%) had FIGO scores of 1 to 2, 8 patients (31%) had scores of 3 to 4, and 10 patients (38%) had scores of 5 to 6. This last group is clinically important because patients at the upper end of the low-risk category are more likely to fail single-agent therapy.
Efficacy
The central efficacy signal was strong. Serum hCG normalized in 96.2% of evaluable patients, with a 90% confidence interval of 85.9% to 97.9%. In practical terms, this means that nearly all treated patients achieved the biological endpoint required to stop therapy and proceed to consolidation. The study also reported durable disease control: after a median follow-up of 41 months, no relapses were observed.
For a disease in which long-term cure and preservation of reproductive potential are both major goals, these results are notable. The absence of relapse over a relatively long follow-up period strengthens the argument that the observed hCG responses were not merely transient biochemical effects, but reflected sustained remission.
Safety and tolerability
The regimen demonstrated an acceptable safety profile. One dose-limiting toxicity occurred, specifically grade 3 sepsis related to a central venous catheter. Immune-related and treatment-related adverse events of grade 2 or higher occurred in 6 patients (22%). These events fully resolved in all but one case of grade 2 dysthyroidism, indicating that most toxicities were manageable and reversible. Importantly, no grade 4 or higher adverse events were reported.
From a clinical standpoint, this safety profile is encouraging because it suggests that adding avelumab did not produce a large burden of severe immune toxicity in a population where treatment is often delivered with curative intent and a low threshold for toxicity is important. Still, the trial size was modest, so uncommon immune-mediated harms could have been missed.
Fertility outcomes
Fertility preservation is a critical issue in gestational trophoblastic disease because many patients are of reproductive age and can often expect future pregnancy after cure. Among patients with childbearing potential and pregnancy intention, 13 of 14 achieved pregnancy, corresponding to 93%. This is a clinically meaningful outcome and supports the idea that intensification with avelumab did not obviously compromise reproductive potential in the short to medium term.
However, fertility success in this setting depends on many factors, including patient age, prior obstetric history, and personal choice, so these results should be interpreted as reassuring rather than definitive evidence of reproductive safety.
Expert Commentary
The TROPHAMET trial addresses an important therapeutic gap. Standard single-agent methotrexate cures most patients with low-risk GTT, but not all. For patients at the higher end of the low-risk range, initial resistance can prolong treatment, increase exposure to chemotherapy, and delay remission. Avelumab-based intensification offers a biologically plausible strategy to improve early disease control.
The study has several strengths. It was multicenter, used a clearly defined low-risk population, incorporated a clinically relevant biomarker-driven endpoint, and included long follow-up with fertility data. The near-universal hCG normalization rate and lack of relapse are especially compelling in a disease where cure is the expected goal.
At the same time, important limitations must be emphasized. This was a nonrandomized trial without a concurrent control group, so the incremental benefit of adding avelumab over methotrexate alone cannot be quantified. The sample size was small, and the study population came from academic referral centers, which may limit generalizability to broader practice settings. In addition, the follow-up, although relatively long for this rare disease, may still be insufficient to fully characterize late immune-related toxicities or rare reproductive outcomes.
Mechanistically, the result is plausible: PD-L1 blockade may enhance antitumor immune recognition in trophoblastic tumors, which are known to interact with the maternal immune system in a unique biologic context. That said, translational plausibility does not replace the need for comparative evidence. A randomized study would be needed to determine whether the combination truly improves cure rates, reduces treatment duration, or benefits the subgroup of patients most at risk for methotrexate failure.
In contemporary practice, the findings are best viewed as hypothesis-generating but highly promising. They may be particularly relevant if future studies confirm that adding immunotherapy early can reduce the need for salvage regimens in patients with borderline low-risk disease.
Conclusion
TROPHAMET suggests that avelumab plus methotrexate is a feasible and potentially more effective first-line strategy for low-risk gestational trophoblastic tumors. The regimen achieved high hCG normalization rates, durable remission, acceptable toxicity, and favorable fertility outcomes. While the results are encouraging, the absence of randomization means the combination should not yet replace standard care. Comparative trials are now needed to define whether immunochemotherapy should become a new first-line option, especially for patients most likely to develop methotrexate resistance.
Funding and ClinicalTrials.gov
Trial registration: ClinicalTrials.gov Identifier NCT04396223.
Funding details were not provided in the abstract text supplied here.
References
1. You B, Lotz JP, Descargues C, et al. Avelumab Plus Methotrexate for Gestational Trophoblastic Tumors: The TROPHAMET Phase 1/2 Nonrandomized Clinical Trial. JAMA Oncology. 2026; PMID: 42275082.
2. FIGO Committee on Gynecologic Oncology. Gestational trophoblastic disease: management guidelines and scoring systems for risk stratification. Relevant guideline documents and reviews on gestational trophoblastic neoplasia and methotrexate-based therapy.
Article Category
OB/GYN & Women’s Health, Oncology
AI Thumbnail Prompt
Professional medical illustration of a female reproductive cell and placenta-like trophoblastic tumor cells with an intravenous immunotherapy infusion bag labeled “avelumab” and a chemotherapy syringe labeled “methotrexate,” set in a modern oncology clinic, clean scientific style, blue and teal tones, high-detail, editorial healthcare thumbnail.
